These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 32059794)

  • 1. Structural Basis for a Convergent Immune Response against Ebola Virus.
    Cohen-Dvashi H; Zehner M; Ehrhardt S; Katz M; Elad N; Klein F; Diskin R
    Cell Host Microbe; 2020 Mar; 27(3):418-427.e4. PubMed ID: 32059794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope.
    West BR; Moyer CL; King LB; Fusco ML; Milligan JC; Hui S; Saphire EO
    mBio; 2018 Sep; 9(5):. PubMed ID: 30206174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The induction and characterization of monoclonal antibodies specific to GP of Ebola virus.
    Tian X; Chen D; Wang H; Xu S; Zhu L; Wu X; Wu Z
    J Med Virol; 2020 Aug; 92(8):996-1006. PubMed ID: 31663613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
    Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
    J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies.
    Murin CD; Gilchuk P; Ilinykh PA; Huang K; Kuzmina N; Shen X; Bruhn JF; Bryan AL; Davidson E; Doranz BJ; Williamson LE; Copps J; Alkutkar T; Flyak AI; Bukreyev A; Crowe JE; Ward AB
    Cell Rep; 2021 Apr; 35(2):108984. PubMed ID: 33852862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
    Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
    J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving cross-reactivity with pan-ebolavirus antibodies.
    King LB; Milligan JC; West BR; Schendel SL; Ollmann Saphire E
    Curr Opin Virol; 2019 Feb; 34():140-148. PubMed ID: 30884329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and molecular basis for Ebola virus neutralization by protective human antibodies.
    Misasi J; Gilman MS; Kanekiyo M; Gui M; Cagigi A; Mulangu S; Corti D; Ledgerwood JE; Lanzavecchia A; Cunningham J; Muyembe-Tamfun JJ; Baxa U; Graham BS; Xiang Y; Sullivan NJ; McLellan JS
    Science; 2016 Mar; 351(6279):1343-6. PubMed ID: 26917592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection.
    Davis CW; Jackson KJL; McElroy AK; Halfmann P; Huang J; Chennareddy C; Piper AE; Leung Y; Albariño CG; Crozier I; Ellebedy AH; Sidney J; Sette A; Yu T; Nielsen SCA; Goff AJ; Spiropoulou CF; Saphire EO; Cavet G; Kawaoka Y; Mehta AK; Glass PJ; Boyd SD; Ahmed R
    Cell; 2019 May; 177(6):1566-1582.e17. PubMed ID: 31104840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.
    Williamson LE; Flyak AI; Kose N; Bombardi R; Branchizio A; Reddy S; Davidson E; Doranz BJ; Fusco ML; Saphire EO; Halfmann PJ; Kawaoka Y; Piper AE; Glass PJ; Crowe JE
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30728263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of an antibody for pan-ebolavirus therapy.
    Furuyama W; Marzi A; Nanbo A; Haddock E; Maruyama J; Miyamoto H; Igarashi M; Yoshida R; Noyori O; Feldmann H; Takada A
    Sci Rep; 2016 Feb; 6():20514. PubMed ID: 26861827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40.
    Yu DS; Weng TH; Shen L; Wu XX; Hu CY; Wang FXC; Wu ZG; Wu HB; Wu NP; Li LJ; Yao H
    Cell Physiol Biochem; 2018; 50(3):1055-1067. PubMed ID: 30355918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 15. Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it.
    Lee JE; Saphire EO
    Curr Opin Struct Biol; 2009 Aug; 19(4):408-17. PubMed ID: 19559599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus.
    Audet J; Wong G; Wang H; Lu G; Gao GF; Kobinger G; Qiu X
    Sci Rep; 2014 Nov; 4():6881. PubMed ID: 25375093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine Generation of Protective Ebola Antibodies and Identification of Conserved B-Cell Signatures.
    Cagigi A; Misasi J; Ploquin A; Stanley DA; Ambrozak D; Tsybovsky Y; Mason RD; Roederer M; Sullivan NJ
    J Infect Dis; 2018 Nov; 218(suppl_5):S528-S536. PubMed ID: 30010811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP.
    Reynard O; Volchkov VE
    J Infect Dis; 2015 Oct; 212 Suppl 2():S372-8. PubMed ID: 26232760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A highly immunogenic fragment derived from Zaire Ebola virus glycoprotein elicits effective neutralizing antibody.
    Wang Y; Liu Z; Dai Q
    Virus Res; 2014 Aug; 189():254-61. PubMed ID: 24930448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice.
    Chen T; Li D; Song Y; Yang X; Liu Q; Jin X; Zhou D; Huang Z
    Antiviral Res; 2017 Sep; 145():54-59. PubMed ID: 28733113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.